Boards and Directors
The Management Board
The Management Board is responsible for running the business of Ottobock SE & Co. KGaA. Chairman of the Board is Professor Hans Georg Näder. The Management Board determines the company’s basic orientation and strategic direction. It consists of four Non-Executive Directors and three of the five Executive Directors (CEO, CFO and CSO) at present.
The Supervisory Board
The European Supervisory Board monitors the activities of the Management Board. The Supervisory Board consists of six shareholder representatives and four employee representatives. Dr Bernd Bohr, long-standing head of the automotive division at Bosch, is Chair of the Supervisory Board.
Philipp Schulte-Noelle – Chief Executive Officer (CEO)
Philipp Schulte-Noelle has been a member of Ottobock’s Executive Board and the Management Board since August 2018. As CEO, he has been responsible since November 2018 for Legal, Corporate Strategy and M&A, Human Resources and Communications, the digital agenda and the Ottobock Human Mobility and Industrials business units, among other duties.
Before joining Ottobock, Schulte-Noelle initially oversaw corporate business development/mergers and acquisitions at international health care company Fresenius SE & Co. KGaA. Most recently he served as Chief Financial Officer and Head of Compliance as well as Chief Human Resources Officer at pharmaceutical and med-tech company Fresenius Kabi AG, based in Bad Homburg, Germany. Prior to that, Schulte-Noelle acquired relevant experience with private equity firm Permira Beteiligungsberatung GmbH in Frankfurt and as a financial analyst at Goldman Sachs International, an investment bank in London.
A native of Cologne, Schulte-Noelle received a degree in business law from the University of Bayreuth and holds an MBA from the international graduate business school INSEAD.
Jörg Wahlers – Chief Financial Officer (CFO)
Jörg Wahlers has been CFO of Ottobock and a member of the Management Board since August 2019. As CFO he is responsible for the key areas of IT and Business Process Management in addition to Finance and Corporate Audit & Risk Management.
Before joining Ottobock, Wahlers worked as CFO and COO for outdoor specialist Jack Wolfskin, where he coordinated the successful sale to Callaway. A UAS graduate in financial management services, Wahlers gained financing and capital market experience at Villeroy & Boch, a company listed in the S-DAX stock market index. He also held management positions at Escada (CFO and COO), Reckitt Benckiser and EFFEM, the pet food division of MARS.
Oliver Jakobi – Chief Sales Officer (CSO)
Oliver Jakobi has been a member of Ottobock’s Executive Board and Management Board since January 2020 in his role of Chief Sales Officer (CSO). As CSO, Jakobi oversees the company’s global business and manages its regions and markets. This also includes its more than 160 Patient Care businesses worldwide.
Jakobi has been with the company for 30 years. Most recently, he successfully headed up the EEMEA region and drove its development in the role of Regional President. He will also continue to manage this region directly in future.
A sales manager with international experience, Jakobi is a native of the Eichsfeld region and completed training as an industrial management assistant (German: Industriekaufmann) at Ottobock. He received his executive master of business administration from the ZfU International Business School in Thalwil, Switzerland. Jakobi relocated to Russia in 1995 to work for the company and has lived in Moscow since then.
Dr Andreas Goppelt – Chief Technology Officer (CTO)
As Chief Technology Officer (CTO), Andreas Goppelt (PhD) has been responsible for Research and Development at Ottobock since September 2017. In 2015 he joined the Ottobock Group as Managing Director of nstim NeuroBionics GmbH, and later was also named Managing Director of Otto Bock Mobility Solutions GmbH, the company’s wheelchair business.
Between 2013 and 2015 he served as a consultant for various manufacturers of biopharmaceuticals and medical technology. From 2005 to 2013, he led R&D for the BioSurgery and Regenerative Medicine business unit at Baxter Healthcare. In 1997 he co-founded biotech company Switch Biotech AG, which specialised in curing wound healing disorders and skin diseases, serving as Chief Scientific Officer.
Andreas Goppelt studied chemistry at Ludwig Maximilian University (LMU) in Munich and earned his doctorate in biochemistry, and performed post doctorate work at LMU’s Gene Center and the Max-Planck Institute for Biochemistry in Martinsried, Germany.
Arne Jörn – Chief Operations Officer (COO)
Arne Jörn has been Chief Operations Officer at Ottobock since March 2018. In this role, he has global responsibility for Facility Management, Production, Quality Management, Purchasing, Logistics and After-Sales-Service.
Jörn began working for global, listed commercial vehicle supplier SAF Holland in 2012, most recently holding the position of COO there as well. He gained experience as a manager in production over the course of several years as plant manager at STILL and director of operations at NORGREN, and was responsible for the strategic and operational direction of the plants and operations.
Jörn was born in Bad Gandersheim, Germany, and studied mechanical engineering at the Technical University of Braunschweig. He later completed a degree in industrial engineering which involved studying in Braunschweig, Hanover and Darmstadt. Jörn previously completed training as a toolmaker at Renold, a company which produces drive technology at its site in Einbeck, Germany.